BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21440552)

  • 1. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
    Dhandapany PS; Fabris F; Tonk R; Illaste A; Karakikes I; Sorourian M; Sheng J; Hajjar RJ; Tartaglia M; Sobie EA; Lebeche D; Gelb BD
    J Mol Cell Cardiol; 2011 Jul; 51(1):4-15. PubMed ID: 21440552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
    Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
    Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Raf1 a nexus for cardiac hypertrophic signaling in human disease?
    Del Re DP; Sadoshima J
    J Mol Cell Cardiol; 2011 Jul; 51(1):1-3. PubMed ID: 21539844
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome.
    Yin JC; Platt MJ; Tian X; Wu X; Backx PH; Simpson JA; Araki T; Neel BG
    Nat Commun; 2017 May; 8():15518. PubMed ID: 28548091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
    Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
    J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
    Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
    Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
    Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
    J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues.
    Nakhaei-Rad S; Haghighi F; Bazgir F; Dahlmann J; Busley AV; Buchholzer M; Kleemann K; Schänzer A; Borchardt A; Hahn A; Kötter S; Schanze D; Anand R; Funk F; Kronenbitter AV; Scheller J; Piekorz RP; Reichert AS; Volleth M; Wolf MJ; Cirstea IC; Gelb BD; Tartaglia M; Schmitt JP; Krüger M; Kutschka I; Cyganek L; Zenker M; Kensah G; Ahmadian MR
    Commun Biol; 2023 Jun; 6(1):657. PubMed ID: 37344639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
    Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
    Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy.
    Oceandy D; Pickard A; Prehar S; Zi M; Mohamed TM; Stanley PJ; Baudoin-Stanley F; Nadif R; Tommasi S; Pfeifer GP; Armesilla AL; Cartwright EJ; Neyses L
    Circulation; 2009 Aug; 120(7):607-16. PubMed ID: 19652091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
    Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
    Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
    Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
    Schramm C; Edwards MA; Krenz M
    J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropisetron inhibits high glucose-induced calcineurin/NFAT hypertrophic pathway in H9c2 myocardial cells.
    Asadi F; Razmi A; Dehpour AR; Shafiei M
    J Pharm Pharmacol; 2016 Apr; 68(4):485-93. PubMed ID: 26945895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New findings in Noonan syndrome and Leopard syndrome: activating mutations in RAF-1 and SOS-1].
    Dereure O
    Ann Dermatol Venereol; 2008; 135(8-9):624-5. PubMed ID: 18789305
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytosolic CARP promotes angiotensin II- or pressure overload-induced cardiomyocyte hypertrophy through calcineurin accumulation.
    Chen C; Shen L; Cao S; Li X; Xuan W; Zhang J; Huang X; Bin J; Xu D; Li G; Kitakaze M; Liao Y
    PLoS One; 2014; 9(8):e104040. PubMed ID: 25089522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
    Li H; Gao S; Ye J; Feng X; Cai Y; Liu Z; Lu J; Li Q; Huang X; Chen S; Liu P
    Mol Cell Endocrinol; 2014 Feb; 382(2):998-1006. PubMed ID: 24291639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.